- Home
- TPST
TPST
Tempest Therapeutics Inc.
as 04-01-2025 3:43pm EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $9.33 | AVG Volume (30 days): | 488.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $6.00 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tempest Therapeutics Inc. News
TPST Breaking Stock News: Dive into TPST Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
7 days ago
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
19 days ago
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
2 months ago
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
GlobeNewswire
2 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3 months ago
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
GlobeNewswire
4 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The Wall Street Journal
4 months ago
A ‘Reverse Aging’ Guru’s Trail of Failed Businesses
Compare TPST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TPST Tempest Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.